The Clinical Significance of Activated p-AKT Expression in Peripheral T-cell Lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Jung Yong | - |
dc.contributor.author | Hong, Min Eui | - |
dc.contributor.author | Choi, Moon Ki | - |
dc.contributor.author | Chang, Wonjin | - |
dc.contributor.author | Do, In-Gu | - |
dc.contributor.author | Jo, Ji-Suk | - |
dc.contributor.author | Jung, Sin-Ho | - |
dc.contributor.author | Park, Silvia | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Ko, Young Hyeh | - |
dc.contributor.author | Kim, Won Seog | - |
dc.date.accessioned | 2023-03-08T19:15:24Z | - |
dc.date.available | 2023-03-08T19:15:24Z | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.issn | 1791-7530 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/64604 | - |
dc.description.abstract | Background: The oncogenic PI3K/serine-threonine kinase (PI3K/AKT) pathway is a downstream pathway of B-cell receptor (BCR) signaling pathway and plays a crucial role in the pathogenesis of B-cell lymphoma. However, there have been preclinical data showing PI3K/AKT pathway activation in T-cell lymphoma, with in different mechanisms from those in B-cell lymphoma. In this study, we investigated the impact of p-AKT expression on clinical outcomes of peripheral T-cell lymphoma (PTCL). Materials and Methods: We analyzed 63 patients with PTCL [PTCL-not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) or extranodal natural kiler T-cell lymphoma (NKTCL)]. To define the clinical implications of p-AKT expression in PTCL, we calculated arbitrary units (AUs) by multiplying the intensity and the proportion of p-AKT expression. Results: Based on a cutoff value of the upper limit of the third quartile (Q3) of the AU, 12 patients were classified into the high p-AKT group, while the remaining 51 patients were classified into the low p-AKT group. The overall response rate to frontline chemotherapy was significantly lower in the high p-AKT group than in the low p-AKT group (20.0% vs. 71.1%, p=0.004). The high p-AKT group showed substantially worse overall survival (OS) (median OS=2.3 vs. 25.2 months, p<0.001) and progression-free survival (PFS) (median PFS=1.6 vs. 8.8 months, p<0.001) compared with the low p-AKT group. Multivariate analysis showed that high p-AKT expression remained a significant independent poor prognostic factor for OS (hazard ratio (HR)=7.0; 95% confidence interval (CI)=3.0-16.6; p<0.001) and PFS (HR=6.8; 95% CI=3.0-15.2; p<0.001). Conclusion: PTCL patients with high p-AKT expression showed aggressive clinical courses with significantly worse OS and PFS and a poor chemotherapy response rate. We suggest that targeting the PI3K/AKT pathway may be a promising therapeutic strategy for PTCL. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | INT INST ANTICANCER RESEARCH | - |
dc.title | The Clinical Significance of Activated p-AKT Expression in Peripheral T-cell Lymphoma | - |
dc.type | Article | - |
dc.identifier.bibliographicCitation | ANTICANCER RESEARCH, v.35, no.4, pp 2465 - 2474 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000352731600080 | - |
dc.identifier.scopusid | 2-s2.0-84928392807 | - |
dc.citation.endPage | 2474 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 2465 | - |
dc.citation.title | ANTICANCER RESEARCH | - |
dc.citation.volume | 35 | - |
dc.type.docType | Article | - |
dc.publisher.location | 그리이스 | - |
dc.subject.keywordAuthor | peripheral T-cell lymphoma | - |
dc.subject.keywordAuthor | PI3K/AKT pathway | - |
dc.subject.keywordAuthor | p-AKT | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | TARGETING BTK | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | IDELALISIB | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | CHOP | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | IBRUTINIB | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.